

REVIEW

Open Access

Role of mesenchymal cells in the natural history of ovarian cancer: a review

Cyril Touboul^{1,2†}, Fabien Vidal^{3,4,5*†}, Jennifer Pasquier^{3,4}, Raphael Lis⁴ and Arash Rafii^{3,4}

Abstract

Background: Ovarian cancer is the deadliest gynaecologic malignancy. Despite progresses in chemotherapy and ultra-radical surgeries, this locally metastatic disease presents a high rate of local recurrence advocating for the role of a peritoneal niche. For several years, it was believed that tumor initiation, progression and metastasis were merely due to the changes in the neoplastic cell population and the adjacent non-neoplastic tissues were regarded as bystanders. The importance of the tumor microenvironment and its cellular component emerged from studies on the histopathological sequence of changes at the interface between putative tumor cells and the surrounding non-neoplastic tissues during carcinogenesis.

Method: In this review we aimed to describe the pro-tumoral crosstalk between ovarian cancer and mesenchymal stem cells. A PubMed search was performed for articles published pertaining to mesenchymal stem cells and specific to ovarian cancer.

Results: Mesenchymal stem cells participate to an elaborate crosstalk through direct and paracrine interaction with ovarian cancer cells. They play a role at different stages of the disease: survival and peritoneal infiltration at early stage, proliferation in distant sites, chemoresistance and recurrence at later stage.

Conclusion: The dialogue between ovarian and mesenchymal stem cells induces the constitution of a pro-tumoral mesenchymal niche. Understanding the dynamics of such interaction in a clinical setting might propose new therapeutic strategies.

Keywords: Mesenchymal stem cells, Ovarian cancer, Crosstalk, Phenotypic modulation, Dissemination, Chemoresistance

Introduction

Ovarian cancer is the most lethal gynecologic malignancy in developed countries, responsible for 5.8% of cancer related deaths [1]. The mainstay of treatment involves cytoreductive surgery associated with platinum and taxane-based chemotherapy [2]. Despite tremendous progresses in surgical practice and the broad range of chemotherapy or targeted therapy available, only low improvement has been achieved in survival outcomes these past 10 years [3-11]. Patients' clinical course remains unpredictable, although most of them are optimally treated, with no residual disease after surgical debulking: 60% of

women presenting with advanced-stage at baseline will recur within 5 years [12,13]. Therefore, 5-year overall survival remains low (around 45% including all stages) mainly due to peritoneal recurrences, suggesting the existence of occult sanctuaries where cancer cells are protected against treatment. Several authors have determined tumor autonomous parameters associated with treatment resistance [14,15]. Moreover, heterogeneity of ovarian cancers between and within subtypes has been illustrated by transcriptomic and genetic profiling [16]. Finally copy number variation analysis has revealed significant differences between matched primary ovarian tumor and peritoneal metastases [17]. Beyond these cell autonomous features, tumor environment may also contribute to the development of clinical relapse.

Tissues are comprised of different cell types that communicate to maintain homeostasis [18]. While architecture of normal tissue is lost in cancer, tumor cells maintain

* Correspondence: dox_94@yahoo.fr

†Equal contributors

³Stem Cell and Microenvironment Laboratory, Weill Cornell Medical College in Qatar, Education City, Qatar Foundation, Doha, Qatar

⁴Department Genetic Medicine, Weill Cornell Medical College, Manhattan, NY, USA

Full list of author information is available at the end of the article

many interactions with surrounding non-malignant cells and extra-cellular matrix (ECM) to create a specific tumor contexture [19]. Both primary and metastatic lesions get infiltrated by diverse stromal cell types, including endothelial cells (ECs), immune cells, fibroblasts and bone marrow-derived cells such as macrophages, mast cells and mesenchymal stem cells (MSCs) [20]. Stromal cells contribute to cancer growth and metastasis, through modulation of different pathways [21-27]. The interactions between cancer and stromal cells are thus primordial for tumor biology as the corresponding crosstalk induces phenotype changes resulting in stromal "activation" and tumor promotion in both primary and metastatic sites [28,29]. Therefore, the microenvironment plays a major role in cancer spread, beyond tumor cell autonomous mechanisms [30] and might have clinical consequences [31].

Understanding the mechanisms governing the relationship between cancer and stromal cells is thus essential to target tumor progression. Among the different peritoneal cells, MSCs are a cornerstone for cancer spread through their participation in the establishment of the pre-metastatic niche and the induction of metastatic and chemo-resistant phenotypes [21,22,25,32-34]. Here we review the complex role of mesenchymal cells in ovarian cancer progression and subsequently illustrate the constitution of a multi-parameter "mesocrine" niche.

Mesenchymal stem cells: a multipotent partner

Although they were initially described in the bone marrow [35-38], MSCs may participate to the constitution of the blood vessel walls and thus be ubiquitous cells, belonging to virtually all organs [39-41]. As a subset of pericytes, they can potentially originate from a perivascular niche [42-46]. MSCs are adherent cells that have a fibroblastic morphology (Figure 1). They are capable of forming colonies (termed colony-forming unit fibroblastic) when selected by adhering to plastic surfaces [38]. Their identification is based on diverse surface markers, including CD105, CD73, CD90, CD166, CD44 and CD29.

MSCs play a major role in tissue homeostasis through the following characteristics: stemness, self-renewal and multipotency [47]. Their participation in tissue repair has been suggested by their capacity to differentiate in different cell types including osteoblasts, adipocytes and chondrocytes [38,48-50]. However, they usually do not differentiate into resident cell types of injured tissue as supported by the therapeutic value of their conditioned media [51]. Furthermore they exhibit low and transient engraftment in the damaged organs [52]. Their reparative function may thus operate through paracrine ("mesocrine") factors [53].

MSCs also serve as niche cells for other cell types, by regulating regenerative processes. Indeed, they participate

to both hematopoietic cells expansion and hematopoietic stem cells (HSCs) regulation [54-57]. In particular, they contribute to self-renewal and differentiation of HSCs through their regulation of the osteogenic niche [58-61].

MSCs have a primordial role in immune tolerance [42,62]. Their immunosuppressive effect on T lymphocytes and dendritic cells may prevent self-responses in both physiological and pathological conditions [63,64]. In addition to their regenerative and immunomodulatory properties, MSCs contribute to tissue healing through many trophic abilities, such as: (i) inhibition of apoptosis and fibrosis; (ii) stimulation of angiogenesis; (iii) recruitment and regulation (proliferation and differentiation) of stem and progenitor cells; (iv) attenuation of oxidative stress [65]. Therefore, they display a wide range of functions, including cell regeneration, immunomodulation and stimulation of angiogenesis. Considering their diverse abilities, MSCs may thus constitute a key cell in the neoplastic niche, as supported by their incorporation into the stroma of solid tumors [66-68] (Figure 2).

MSCs engraftment into tumoral stroma leads to pro-tumoral crosstalk

Recruitment of cancer-associated MSCs

Bone marrow-derived MSCs are mobilized in blood circulation of patients presenting with advanced-stage ovarian cancer [34]. Interestingly, they normalize after complete cyto-reductive surgery. Such observation indicates a potential role for the interactions between ovarian cancer cells (OCCs) and MSCs during tumorigenesis.

Indeed, tumors act as unhealed wounds producing a continuous source of inflammatory mediators [69], resulting in the recruitment of other cell types, including MSCs [70-72]. Cancer cells hijack the cytokine machinery to acquire phenotypic advantages in proliferation [73], angiogenesis [74] and invasive and migratory properties [75-77]. The cytokine machinery is thus widely deregulated in advanced ovarian cancer, as supported by the amplification of many genes encoding cytokines in OCCs [17,78]. Such deregulation leads to bone marrow-derived and resident-tissue MSCs engraftment into tumor stroma through increased release of chemo-attractant soluble factors [79]. Many cytokines are involved in their recruitment, including IL-6, SDF1 (stroma derived factor 1), prostaglandine E2 (PGE2), PDGF and LL-37 (leucine, leucine-37) [21,80].

Educating MSCs to build a permissive tumoral environment

In ovarian cancer, the crosstalk between tumor and stromal cells leads to bilateral phenotype modulation. Indeed, besides OCCs phenotypic modifications, the phenotype of cancer-associated MSCs will evolve. Although it may differ from a cancer type to another, the shift in MSCs phenotype after their integration into tumor stroma mostly results in




Figure 1 Morphological aspect of Mesenchymal Stem Cells (MSCs) cultivated in vitro. (A) Confocal microscopy showing intercellular interaction through Tunneling Nanotubes. **(B)** Optical microscopy illustrating the classical fibroblast-like shape of MSCs (x10).

tumorigenesis promotion (Figure 3). For instance, breast cancer cells induce MSCs de novo CCL5 (RANTES) secretion which then acts as a paracrine mediator of increased motility, invasion and metastatic abilities of the tumor cells [68]. Once they engraft in ovarian neoplastic microenvironment, cancer-associated MSCs display an expression profile distinct from bone marrow MSCs, with an increased expression of BMP-2, BMP-4 and BMP-6, and a

significant downregulation of PDGFR β and TBX5 [81]. This pro-tumoral shift in phenotype is mediated, at least partially, by tumor-derived secreted factors.

LL-37 enhances MSCs secretion of IL-1 β , IL-6, IL-8, IL-10 and TNF α while diminishing the secretion of IL-12 [82], with a positive impact on tumor growth. MSCs exposed to LL-37 stimulate endothelial cell tube formation *in vitro* suggesting concomitant increased




Figure 2 Mesenchymal Stem Cells (MSCs) co-cultivated in vitro with Ovarian Cancer Cells (OCCs). (A) Confocal microscopy: eGFP-MSCs (green) interact with PKH26-OCCs (red). (B) Optical microscopy showing how cancer and mesenchymal cells organize in vitro (×10).

production of pro-angiogenic molecules. They also migrate around endothelial structures and acquire a pericyte-like differentiation [82]. Lysophosphatidic acid (LPA) is a small bioactive phospholipid produced by OCCs that stimulates differentiation of MSCs in myfibroblast-like cells [83-85]. These activated fibroblasts, also termed cancer-associated fibroblasts (CAFs), are a cornerstone in the

establishment of tumor environment. MSCs incorporation into tumor stroma is thus associated with a morphological shift toward CAF-like phenotype, including expression of myfibroblast-like cell markers (α -SMA, desmin, VEGF), proteins involved in the regulation of ECM structure (Tn-C, Tsp-1, SL-1) and tumor promoting factors [22]. The underlying mechanism governing this differentiation




Figure 3 The cytokine-mediated crosstalk between Mesenchymal Stem Cells (MSCs) and Ovarian Cancer Cells (OCCs) leads to a shift in MSCs phenotype resulting in tumorigenesis promotion. MSCs are recruited to tumor stroma from a peri-vascular niche. Their engraftment is associated with phenotypic modulations in response to tumor-derived secreted factors. Primed MSCs support tumor growth and self-renewal. Their differentiation in cancer-associated fibroblasts (CAFs) contributes to stromal modifications suitable for tumor expansion and stimulates angiogenesis. We highlight the role of HOXA9 expression that results in transcriptional activation of the gene encoding TGFβ2 inducing in turn CAFs expression VEGF.

process may also involve exosomes secreted by the tumor [86]. Interestingly, exosomes from different ovarian cancer cell lines (OVCAR-3 and SKOV-3) activate different MSCs signaling pathways (SMAD and AKT, respectively), suggesting that exosome content may vary according to cancer cell phenotype and thus modulate the tumor stroma differently. A genomic approach also correlates OCCs ability to induce CAFs features in MSCs with the expression of HOXA9, a Mullerian-patterning gene [87]. HOXA9 expression results in transcriptional activation of the gene encoding TGFβ2 that induces MSCs expression of IL-6, VEGF-A and SDF1. Schauer et al. have described a circuit whereby OCCs secrete IL-1β instructing a CAFs niche through p53 inhibition [31]. In return, the CAFs niche secretes IL-8, growth regulated oncogene-alpha (GRO-α), IL-6 and VEGF. Therefore, the modulation of MSCs phenotype contributes to generate a cytokine mediated inflammatory contexture suitable for tumor progression.

Once MSCs differentiate into CAFs they participate in the formation of fibrovascular networks within the tumor [22,88]. CAFs contribute to the perivascular matrix through the production of desmin and α-SMA [22]. CAFs secrete versican, a large ECM proteoglycan which production is up regulated by TGFβ via TGFβ-RII and SMAD signaling [89]. Up regulated versican then promotes OCCs motility. Their expression of the metalloprotease MMP-3 also participates in ECM regulation [22]. The resulting stromal modifications (increased vessel stability and matrix degradation) are compatible with tumor expansion, stimulated simultaneously by CAFs release of tumor-supportive growth factors, including HGF, EGF, IL-6 and SDF1 [88]. Ovarian tumors display increased expression of SDF1 in both CAFs and OCCs. SDF1 actively participates in the development of tumor environment and promotes tumor growth through complex mechanisms. First, it reduces local immunity and

protects cancer cells by increased recruitment of plasmacytoid dendritic cell precursors resulting in poor anti-tumoral T cell activation through local overexpression of IL-10 and TNF α [90,91]. SDF1 also induces a dose-dependent proliferation of OCCs by its specific interaction with the receptor CXCR4, leading to transactivation of EGFR [92]. It participates as well in adhesion and trans-endothelial migration of cancer cells through MAP and Akt kinase regulation [93,94]. SDF1 promotes angiogenesis at tumor sites: hypoxia synchronously stimulates tumor SDF1 and VEGF production resulting in synergistic induction of angiogenesis [95]. SDF1 also acts as a chemo attractant for endothelial progenitor cells (EPCs) CXCR4 + [96].

Noteworthy, direct intercellular interaction participates in phenotypic and environmental changes. Indeed, we have shown in a co-culture setting that MSCs triggered pro-metastatic properties in OCCs, including adherence, invasion and migration through the modification of cancer cells transcriptomic profile [32].

Induction of tumor plasticity: the cancer stem cell (CSC) theory

The CSC theory if clinically confirmed may represent be an extreme form of cancer cell phenotypic plasticity. CSCs are defined with the following criteria: (i) self renewal, (ii) reproducible tumor phenotype, (iii) restricted to a minority among entire cell population, (iv) differentiation into non-tumorigenic cells, (v) expression of distinct cell markers allowing their isolation [97-100]. CSCs have been identified in many solid cancers, including ovarian malignancies [101-109]. The identification of ovarian CSCs is based on CD117 (c-kit), CD44, CD133 and ALDH markers as well as PKH67/PKH26 dyes [99,102,110-112]. According to Silva et al., dual positivity of CD133 and ALDH defines an effective cell population of ovarian CSCs [111]. In limited dilution assays, a small number of these cells are sufficient to initiate tumors. Furthermore, they exhibit an increased angiogenic ability compared to regular OCCs. In the clinical setting, the presence of CSCs in ovarian tumors portends poor survival outcomes, leading to increased tumor burden and chemoresistance [113,114]. Their persistence within a residual niche may therefore contribute to disease recurrences.

We have recently reviewed the role of the microenvironment in ovarian CSCs maintenance [115]. Among the diverse stromal actors, cancer-associated MSCs are determinant for the regulation of CSCs self-renewal via increased expression of BMP-2 [81]. MacLean et al. reported a 4- to 8-fold increase in the percentage of ovarian CSCs in the presence of cancer-associated MSCs. Interestingly, tumor stemness was only partially blocked by the BMP inhibitor Noggin, suggesting the existence of other redundant pathways. MSCs-derived IL-6 and

IL-8, whose production is stimulated by LPA, participate in CSCs promotion: IL-6 contributes to self-renewal of CSCs and IL-8 to CSCs proliferation through its binding to CXCR1 receptor [72,102,103,116,117].

Altogether MSCs engraftment at primary tumor site positively impacts cancer progression, due to the combination of several mechanisms including two-sided phenotypic modulation and promotion of OCCs proliferation and angiogenesis. MSCs also contribute to build a suitable environment that will participate in the regulation of ovarian cancer metastasis.

Metastatic niche: the concept of targeted spread

The "seed and soil" theory revisited

Based on autopsies of patients with breast cancer, Stephen Paget's "seed and soil" theory illustrates the striking fact that a given tumor type will preferentially metastasize to specific organs [118]. This tumor tropism is clearly observed for certain cancers such as breast and prostate adenocarcinomas that commonly metastasize to bone tissue, or ovarian malignancies that typically spread into the peritoneal cavity. One century later, David Tarin reached a similar conclusion in patients with peritoneal carcinomatosis from diverse cancers including primary ovarian tumors [119]. While patients with peritoneovenous shunts had millions of cancer cells poured in their blood circulation, they did not display more distant metastasis nor decreased survival compared to patients without shunts. Moreover, half of them did not develop any distant metastasis up to 27 months survival. Somehow, ovarian cancer is thus "programmed" to spread into selected organs and steer away from others. Besides the intrinsic abilities of cancer cells, tumor environment as well as resident stroma cells of distant sites participate in this targeted metastatic process.

The pre-metastatic niche

Lyden's group has defined the concept of pre-metastatic niche as the early changes that occur in the future metastatic site before engraftment of cancer cells [79,120]. The constitution of such a niche dictates the pattern of metastatic spread. In brief, bone marrow-derived hematopoietic progenitor cells (HPCs) migrate to distant sites in response to growth factors and inflammatory cytokines secreted by the primary tumor. Kaplan et al. describe the existence of a complex loop where HPCs VEGFR1+ form cellular clusters in tumor-specific pre-metastatic sites before the arrival of cancer cells. Resident fibroblasts, possibly derived from MSCs and activated by tumor-specific growth factors, secrete fibronectin, an adhesion protein inducing VLA-4 (integrin $\alpha_4\beta_1$) mediated recruitment of HPCs [29]. $\alpha_4\beta_1$ signaling induces modifications of the local ECM mediated by MMP-9. The microenvironment alteration enhances recruitment

of HPCs VEGFR1+, constituting in return a pre-metastatic contexture through a cytokine network including TNF α , MMP-9, TGF β , and SDF1 [121]. SDF1 finally acts as a chemo-attractant for both hematopoietic progenitor cells (HPCs CXCR4+) and metastatic tumor cells (MTCs). In the hypoxia context, lysyl oxidase secreted by hypoxic tumor cells accumulates at pre-metastatic sites, resulting in CD11b+ myeloid cell recruitment and increased production of MMP-2 [122]. MMP-2 favors tumor cells attachment through the changes they mediate in ECM [123]. MTCs subsequently engraft the permissive niche and contribute to the constitution of micro-metastases.

However, the stromal role during the metastatic process goes beyond the constitution of the pre-metastatic niche. Primary tumor stroma may also participate in selecting clones primed for metastasis in specific organs. In a triple negative breast cancer model, Zhang et al. have demonstrated that a tumor stroma rich in CAFs selects for cancer clones that fit to thrive on the CAF-derived cytokines SDF1 and IGF1 and sheds the carcinoma population toward a preponderance of such clones [124]. These clones display a constitutively high level of Src activity and bone metastatic ability contrary to most triple negative cancers that prominently metastasize to visceral organs. CAFs provide a cytokine contexture (SDF1 and IGF1) similar to bone marrow microenvironment and select metastatic seeds compatible with the target organ.

Altogether, data in the literature support the concept that the stroma actively participates in tumor promotion and to the constitution of a permissive niche for metastatic cells. It is thus a strong determinant of metastatic tropism. While different tumor types have their own physiopathology governing preferential sites for metastasis, ovarian cancer spread at an advanced stage (above IIIC) is limited to the peritoneum and distant blood-borne metastases are quite rare [125,126]. The recurrences are also often located within the abdominal cavity proposing the role of a residual niche within the peritoneum.

Initial dissemination within peritoneal cavity

Initial dissemination of OCCs from primary tumor is based on changes in expression of cellular adhesive proteins (Figure 4). Intercellular adhesion in ovarian tumors is mediated by N- and E-cadherin, and cell-matrix adhesion by integrins [127]. Disruption of both cell-cell contact and cell-matrix interactions results in the shedding of single cells or multicellular aggregates into peritoneal cavity. These ascitic OCCs undergo epithelial-to-mesenchymal-transition, resulting in a phenotype with low levels of E-cadherin and higher invasiveness and motility compared to primary tumor cells [128]. They also display CSCs characteristics when clustered in compact spheres, leading to increased chemoresistance and tumorigenesis [99]. They migrate to distant areas following the

flow of peritoneal fluid hence the geographical localization of lesions within the abdomen at diagnosis. Ascites fluid comprises more than 200 proteins in its soluble fraction, including LPA, SDF1, cytokines such as RANTES, IL-1, IL-6, IL-8 and IL-10, growth factors (EGF, VEGF, HB-EGF, TGF β , TNF α and CSF1) and ECM proteins such as collagens I and III [129-136]. It thus constitutes a suitable environment for OCCs survival.

Cellular components including inflammatory and mesothelial cells are also prevalent in ascites. We have isolated stromal cells from ascites of patients presenting with ovarian cancer [137]. These tumor associated mesenchymal cells (TAMCs) were closely associated with tumor cells (photo) and shared some homology with bone marrow- and adipose- derived MSCs (CD9, CD10, CD29, CD146, CD166, HLA-1) [24]. They might therefore represent a differentiated stromal subset of MSCs. Converging data support that TAMCs actively contribute to metastatic process through different mechanisms. We have shown that intra-peritoneal co-injection of TAMCs and OCCs conferred a proliferative advantage to OCCs in a murine model with enhanced tumor growth and development of neoplastic ascites [24]. Noteworthy, TAMCs were preferentially localised close to cancer cells, typically in the periphery of tumors. Moreover, the presence of TAMCs was associated with increased tumor vascularization. Concomitantly, HIF-1 α and VEGF-A were overexpressed in tumors and ascites, respectively, derived from the group that received co-injection. Castells et al. failed to demonstrate any proliferative effect of TAMCs on ECs [138]. Nevertheless they have shown the existence of a crosstalk between TAMCs and macrophages yielding increased production of pro-angiogenic cytokines, including IL-6, IL-8 and VEGF.


TAMCs also display a protective role by inducing chemoresistance and immunomodulation [23,137,139]. TAMCs inhibit both proliferation and cytokine production in human CD4 and CD8 T-cells, allowing cancer cells to evade immune surveillance. Therefore, the protection TAMCs provide prompts us to consider them as a niche where tumor cells are sheltered against therapy.

Cancer dissemination in ovarian malignancies may be sequential, from the primary tumor to abdominal "milieu" and then to the peritoneum. Indeed, ascitic OCCs might be the primary source of intraperitoneal metastatic lesions. Their attachment to the peritoneum constitutes the first step toward peritoneal infiltration.

Peritoneal carcinomatosis

Peritoneal involvement

Clinical presentation at baseline in patients with advanced stages includes ascites, peritoneal carcinomatosis and omental involvement [140] (Figure 4). The peritoneum is a complex organ constituting the microenvironment of



ovarian cancer metastatic nodules (Figure 5). It is composed of a continuous mesothelial cell layer covering all abdominal organs except ovaries. The peritoneum lies on a basement membrane covering stromal tissue. This stroma contains a collagen-based matrix (collagen types I and III), blood and lymphatic vessels, nerve fibers and fibroblastic-like cells (Figure 6). The peritoneum is considered as a tertiary lymphoid organ that allows fast mobilization and recruitment of the inflammatory machinery to overcome abdominal injury or infection. Hence many inflammatory cytokines are up regulated in ovarian cancer ascites. Mesothelial cells also contribute to peritoneal fluid dialysis, abdominal healing and formation of adhesions [141,142]. Therefore, the peritoneum constitutes a functional and anatomical barrier against

intra-abdominal aggression and is considered as the first line of defense against cancer spread [143,144].

However the metastatic process manages to disrupt the organisation of the mesothelial layer: during the formation of carcinomatosis nodules, mesothelial cells aggregate around the neoplastic lesion [145]. The mechanism used by OCCs to clear mesothelial cells and get access to the basement membrane is complex and yet poorly understood. Tumoral soluble factors may prime mesothelial tissue for cancer spread. Indeed, mesothelium in ovarian carcinomatosis displays morphological changes and forms a discontinuous layer of hemispheric cells [146]. This phenotypic alteration is associated with modifications in transcriptomic profile, including modulation of genes involved in inflammation, catalytic activity,




Figure 5 Macroscopic aspects of peritoneal carcinomatosis. (A) Isolated lesions. (B) Confluent lesions. (C) Typical "taches de bougie" lesions. (D) Miliary lesions.




Figure 6 Pathological aspects of normal peritoneum and peritoneal metastasis.

cellular adhesion and ECM constitution [147]. Analysis of surgical specimens has suggested that mesothelial cells may nurture peritoneal metastases through the production of growth factors such as VEGF and fibroblast growth factor 2 (FGF-2) [148]. The initiation of peritoneal invasion also relies on the ability of OCCs to attach to mesothelial cells through activation of CD44 and beta-1 integrin [149,150]. In their *in vitro* model, Iwanicki et al. have shown that ovarian cancer spheroids use integrin- and talin-dependent activation of myosin and traction force to promote displacement of mesothelial cells [151]. This mesothelial clearance permits OCCs to get access to the basement membrane and to stromal cells that will then support their survival and growth. MSCs play an important role along this process, as supported by our 3D model of early peritoneal infiltration based on amniochorionic membrane [33]. In serum free condition, OCCs became adherent to the membrane within the first 24 hours following incubation and started to infiltrate the stroma 48 hours after adhesion. Infiltration was significantly deeper in areas settled with MSCs, due to increased release of IL-6. Therefore, MSCs generate a cytokine contexture suitable for metastasis establishment. Metalloproteases such as MMP-2 contribute through a feed-forward loop to cancer cells peritoneal adhesion and invasion. MMP-2 expression is up regulated in OCCs upon binding to mesothelium, through direct cell-cell interaction involving mesothelial cells [123]. MMP-2 is also produced by bone marrow-derived MSCs recruited to the tumor site in response to OCCs secretion of LL-37 [21]. MMP-2 over-expression leads to increased degradation of ECM proteins such as vitronectin and fibronectin. OCCs adhere more efficiently to cleaved fragments, resulting in improved attachment. Noteworthy, vitronectin and fibronectin production is increased during the metastatic process. Resident fibroblasts, potentially deriving from resident MSCs, are primed by tumor specific growth factors and constitute the main source of ECM proteins [29].

Omental infiltration

The omentum is a large fold of visceral peritoneum containing fatty tissue. In a 3D culture model of omental infiltration, Kenny et al. have demonstrated that OCCs preferentially adhere to and invade through collagen I and IV rather than fibronectin, vitronectin and laminin [143]. Furthermore, resident cells differently impact the metastatic process. While mesothelial cells inhibit both adhesion and invasion, omental fibroblasts promote OCCs attachment and infiltration. Similarly to peritoneal infiltration, MMP-2 over-expression observed upon the interaction between OCCs and omental fibroblasts may promote tumoral infiltration [123]. Omental MSCs (O-ASCs) also participate in the invasion process

[152]. In a model of endometrial carcinoma, O-ASCs stimulated cancer cells proliferation and promoted *in vivo* tumor growth and vascularization [152]. Compared to the control group, the tumors associated with O-ASCs contained a more mature and extensive fibrovascular network. These findings can be extrapolated to the omental invasion occurring in ovarian cancer (Figure 7).

MSCs and chemoresistance

Microenvironment mediates resistance to therapy

The mainstay of treatment for ovarian cancer involves complete cyto-reductive surgery associated with platinum and taxane-based chemotherapy [153]. However, most patients achieving complete initial clinical remission will develop recurrences and resistance to first line drugs [154-156]. Acquired chemoresistance involves many mechanisms: (i) alteration of the lipid membrane modifying drug penetrance; (ii) increased capacity in DNA repair; (iii) modification of drug targets; (iv) drug inactivation mediated by metallothionein- or glutathione-dependent mechanisms; (v) loss of drug surface transporter; (vi) drug clearance by efflux pump [137]. Such resistance mechanisms consist in long-term processes and usually arise after multiple courses of chemotherapy [155,157]. They develop over time as a result of sequential genetic changes that ultimately culminate in some complex therapy-resistant phenotypes.

However, acquired chemoresistance cannot explain most of treatment failures in ovarian cancer. The majority of recurrences will occur within the first two years following completion of initial treatment. Primary resistance to treatment only concerns a low subgroup of early relapses (up to 6 months after initial treatment). Other diseases are considered platinum-sensitive. Therefore, in addition to casual mechanisms of acquired resistance, the microenvironment might mediate a kind of *de novo* drug resistance leading to the persistence of a hidden residual disease responsible for a subsequent relapse.

First evidences were provided in 1990 by Teicher et al. [158]. In a murine breast cancer model, long-term exposure to treatment was responsible for chemoresistance in tumor-bearing animals. Nevertheless, in spite of high levels of *in vivo* resistance, no significant resistance was observed when cancer cells were exposed to the same drugs *in vitro*. These findings set up the stage for the paradigm that drug resistance can develop through mechanisms that are expressed only *in vivo* and may involve the crosstalk between cancer and stromal cells. Somehow the microenvironment could protect the tumor cells from the effects of anticancer agents.

The cross talk between cancer and stromal cells is responsible for changes in ECM and cytokines release. Reciprocal integrin- and soluble factor-mediated interaction induces in cancer cells a transient drug resistant




Figure 7 Pathological aspects of normal omentum and omental metastasis.

phenotype leading to persistence of surviving cells [157]. Over time, genetic instability inherent to tumor cells combined with selective pressure of therapy will result in successive and random genetic changes. Such modifications will cause the gradual development of more complex and permanent acquired-resistance phenotypes, and relapses may originate from these persistent cancer cells.

MSCs actively contribute to environment-mediated resistance

The microenvironment provides a transient protection while OCCs are acquiring genetic changes. Oncologic trogocytosis perfectly illustrates this mechanism: through a membrane uptake, cancer cells can get new functionalities. We have observed such hetero-cellular interaction between TAMCs and OCCs [137]. Trogocytosis allowed OCCs to acquire functional multidrug resistance proteins from TAMCs membrane, including P-gp and LRP. Such mechanisms have been described in other tumors as well [159,160].

MSCs are responsible for phenotypic modulation toward more aggressive cancer cell clones. We have proposed a transcriptomic approach in OCCs co-cultured with MSCs [32]. The analysis revealed that 3 biological-function gene clusters were enriched in OCCs upon contact with MSCs, comprising metastatic, proliferative and chemoresistance abilities. Concordantly, OCCs co-cultured with MSCs displayed chemoresistance to taxol and carboplatin. MSCs-derived secreted factors are also

able to confer chemoresistance to platinum in OCCs, as supported by the decrease of carboplatin-induced apoptosis in the presence of MSCs condition medium [139]. This apoptosis blockade is mediated by the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway and the phosphorylation of its downstream regulator X-linked inhibitor of apoptosis (XIAP).

Microenvironment protection may have contributed to the disappointing results of hyperthermic intraoperative chemotherapy (HIPEC) for stage IIIC ovarian cancers [161,162]. HIPEC procedure involves a complete resection of abdominal disease followed by intra peritoneal infusion of Oxaliplatin at 42-44°C. We have demonstrated that hyperthermia did not challenge survival of bone marrow-derived and cancer-associated MSCs [25]. Furthermore, in the context of hyperthermia, MSCs induced a thermo tolerance in OCCs through SDF1 secretion. The inhibition of SDF1/CXCR4 interaction restored cytotoxicity of hyperthermia.

Circulating MSCs, observed in advanced-stage ovarian malignancies, are also involved in chemoresistance. They are activated by platinum-derived drugs and in turn secrete fatty acids (PIFAs) that, in discrete quantities, confer OCCs resistance to several types of anti-cancer agents [34]. PIFAs induce acute and reversible prevention of apoptosis in cancer cells through an indirect and yet undetermined effect that can be prevented by concomitant infusion of cyclooxygenase-1 inhibitor.




Figure 8 Overview of the role of Mesenchymal Stem Cells along tumorigenesis.

MSCs widely participate in drug resistance in ovarian cancer through many mechanisms. Anti-tumor therapy should thus be associated to additional therapies targeting tumor-stroma interactions. Such therapeutic combination would prevent from temporary microenvironment-mediated drug resistance and might suppress any minimal residual disease. In the era of personalized medicine, it represents one of the biggest challenges for further therapeutic approaches in ovarian cancer.

Conclusion

Tumor stroma and microenvironment represent a cornerstone in the regulation of OCCs behavior (Figure 8). MSCs contribute to each step of cancer spread, from proliferation to chemoresistance, from infiltration to metastasis. The crosstalk between MSCs and OCCs is based on complex mechanisms, involving cell-cell interaction and secreted factors. Beyond casual phenotypic changes they generate in tumor cells, MSCs provide a smart environment-mediated resistance protecting residual disease from treatment while acquired mechanisms are developing. OCCs and MSCs clearly constitute a deadly cocktail, offering the disease a multi-potent partner. Therefore, to enhance suppression of any residual disease, future therapeutic approaches should thus combine anti-tumor therapy to new molecules targeting tumor-stroma interactions.

Abbreviations

ECM: Extra-cellular matrix; EC: Endothelial cell; MSC: Mesenchymal stem cell; HSC: Hematopoietic stem cell; OCC: Ovarian cancer cell; CAF: Cancer associated fibroblast; EPC: Endothelial progenitor cell; CSC: Cancer stem cell; HPC: Hematopoietic progenitor cell; MTC: Metastatic tumor cell; TAMC: Tumor associated mesenchymal cell; HIPEC: Hyperthermic intraoperative chemotherapy.

Competing interest

The authors declare that they have no competing interest.

Authors' contributions

CT carried out manuscript writing and reviewing, and performed bibliographic search. FV carried out manuscript writing and reviewing and figures conception. JP carried out manuscript reviewing and figures conception. RL carried out manuscript reviewing and participated to bibliographic search. AR carried out manuscript writing and reviewing, figures conception and participated to bibliographic search. All authors read and approved the final manuscript.

Acknowledgement

We would like to acknowledge everyone who contributed to this work: Jessica Hoarau, Mahab Maleki, Nadine Abu-Kaoud, Renuka Gupta.

Author details

¹Department of Obstetrics and Gynecology, Hôpital Intercommunal de Créteil, Université Paris Est, UPEC-Paris XII, 12 avenue de Verdun, 94000 Créteil, France. ²UMR INSERM U965: Angiogenèse et Recherche translationnelle Hôpital Lariboisière, 49 bd de la chapelle, 75010 Paris, France. ³Stem Cell and Microenvironment Laboratory, Weill Cornell Medical College in Qatar, Education City, Qatar Foundation, Doha, Qatar. ⁴Department Genetic Medicine, Weill Cornell Medical College, Manhattan, NY, USA. ⁵Department of Genetic Medicine and Obstetrics and Gynecology, Stem Cell and Microenvironment Laboratory, Weill Cornell Medical College in Qatar, Qatar-Foundation PO: 24144, Doha, Qatar.

Received: 16 April 2014 Accepted: 19 September 2014

Published online: 11 October 2014

References

1. Siegel R, Naishadham D, Jemal A: **Cancer statistics, 2012.** *CA Cancer J Clin* 2012, **62**:10–29.
2. Leminen A, Auranen A, Butzow R, Hietanen S, Komulainen M, Kuoppala T, Maenpaa J, Puistola U, Vuento M, Vuorela P, Yliskoski M: **Update on current care guidelines: ovarian cancer.** *Duodecim* 2012, **128**:1300–1301.
3. Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA: **Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study.** *Gynecol Oncol* 2012, **127**(3):495–501.
4. Mobus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA: **Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.** *J Clin Oncol* 2007, **25**:4187–4193.
5. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: **Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.** *J Clin Oncol* 2003, **21**:283–290.
6. Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM: **Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.** *Gynecol Oncol* 2012, **125**:640–645.
7. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P: **Randomized, open-label, phase III study comparing paupirone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.** *J Clin Oncol* 2012, **30**:3841–3847.
8. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX: **Incorporation of bevacizumab in the primary treatment of ovarian cancer.** *N Engl J Med* 2011, **365**:2473–2483.
9. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM: **A phase 3 trial of bevacizumab in ovarian cancer.** *N Engl J Med* 2011, **365**:2484–2496.
10. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U: **Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.** *N Engl J Med* 2012, **366**:1382–1392.
11. Jaabak K, Johnson N, Lawrie TA: **Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.** *Cochrane Database Syst Rev* 2011, **11**:CD005340.
12. Poveda Velasco A, Casado Herraez A, Cervantes Ruiperez A, Gallardo Rincon D, Garcia Garcia E, Gonzalez Martin A, Lopez Garcia G, Mendiola Fernandez C, Ojeda Gonzalez B: **Treatment guidelines in ovarian cancer.** *Clin Transl Oncol* 2007, **9**:308–316.
13. Burke TW, Morris M: **Secondary cytoreductive surgery for ovarian cancer.** *Obstet Gynecol Clin North Am* 1994, **21**:167–178.
14. Myers ER, Havrilesky LJ, Kulasingam SL, Sanders GD, Cline KE, Gray RN, Berchuck A, McCrory DC: **Genomic tests for ovarian cancer detection and management.** *Evid Rep Technol Assess (Full Rep)* 2006, **145**:1–100.
15. **Integrated genomic analyses of ovarian carcinoma.** *Nature* 2011, **474**:609–615.
16. Farley J, Ozburn LL, Birrer MJ: **Genomic analysis of epithelial ovarian cancer.** *Cell Res* 2008, **18**:538–548.
17. Malek JA, Mery E, Mahmoud YA, Al-Azwani EK, Roger L, Huang R, Jouve E, Lis R, Thierry JP, Querleu D, Rafii A: **Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis.** *PLoS One* 2011, **6**:e28561.
18. Joyce JA, Pollard JW: **Microenvironmental regulation of metastasis.** *Nat Rev Cancer* 2009, **9**:239–252.

19. Udagawa T, Wood M: **Tumor-stromal cell interactions and opportunities for therapeutic intervention.** *Curr Opin Pharmacol* 2010, **10**:369–374.
20. Tlsty TD, Coussens LM: **Tumor stroma and regulation of cancer development.** *Annu Rev Pathol* 2006, **1**:119–150.
21. Coffelt SB, Marini FC, Watson K, Zwezdayk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, Honer zu Bentrup K, Danka ES, Henkle SL, Scandurro AB: **The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.** *Proc Natl Acad Sci U S A* 2009, **106**:3806–3811.
22. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F: **Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression.** *PLoS One* 2009, **4**:e4992.
23. Martinet L, Poupot R, Mirshahi P, Rafii A, Fournier JJ, Mirshahi M, Poupot M: **Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses.** *Int J Cancer* 2010, **126**:2143–2152.
24. Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J, Mirshahi M, Couderc B: **Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis.** *Int J Cancer* 2010, **126**:2090–2101.
25. Lis R, Touboul C, Mirshahi P, Ali F, Mathew S, Nolan DJ, Maleki M, Abdalla SA, Raynaud CM, Querleu D, Al-Azwani E, Malek J, Mirshahi M, Rafii A: **Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12.** *Int J Cancer* 2011, **128**:715–725.
26. St Hill CA: **Interactions between endothelial selectins and cancer cells regulate metastasis.** *Front Biosci* 2012, **17**:3233–3251.
27. Mierke CT: **Role of the endothelium during tumor cell metastasis: is the endothelium a barrier or a promoter for cell invasion and metastasis?** *J Biophys* 2008, **2008**:183516.
28. Cirri P, Chiarugi P: **Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression.** *Cancer Metastasis Rev* 2012, **31**:195–208.
29. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D: **VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.** *Nature* 2005, **438**:820–827.
30. Hanahan D, Weinberg RA: **Hallmarks of cancer: the next generation.** *Cell* 2011, **144**:646–674.
31. Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Urbe I, Sood AK, Huang P, Liu J: **Interleukin-1beta promotes ovarian tumorigenesis through a p53/NF-kappaB-mediated inflammatory response in stromal fibroblasts.** *Neoplasia* 2013, **15**:409–420.
32. Lis R, Touboul C, Raynaud CM, Malek JA, Suhre K, Mirshahi M, Rafii A: **Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties.** *PLoS One* 2012, **7**:e38340.
33. Touboul C, Lis R, Al Farsi H, Raynaud CM, Warfa M, Althawadi H, Mery E, Mirshahi M, Rafii A: **Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model.** *J Transl Med* 2013, **11**:28.
34. Roodhart JML, Daenen LGM, Stigter ECA, Prins H-J, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJG, van Amersfoort M, Vermaat JSP, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PWB, Medema RH, Martens AC, Brenkman AB, Voest EE: **Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.** *Cancer Cell* 2011, **20**:370–383.
35. Caplan AL: **Mesenchymal stem cells.** *J Orthop Res* 1991, **9**:641–650.
36. Tavassoli M, Crosby WH: **Transplantation of marrow to extramedullary sites.** *Science* 1968, **161**:54–56.
37. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA, Rudakow IA: **Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method.** *Exp Hematol* 1974, **2**:83–92.
38. Friedenstein A: **Osteogenic stem cells in bone marrow.** In *Bone and Mineral Research*. Edited by Heersche J, Kanis J. Amsterdam: Elsevier; 1990:243–272.
39. da Silva Meirelles L, Sand TT, Harman RJ, Lennon DP, Caplan AL: **MSC frequency correlates with blood vessel density in equine adipose tissue.** *Tissue Eng Part A* 2009, **15**:221–229.
40. Bernardo ME, Locatelli F, Fibbe WE: **Mesenchymal stromal cells.** *Ann N Y Acad Sci* 2009, **1176**:101–117.
41. Raynaud CM, Maleki M, Lis R, Ahmed B, Al-Azwani I, Malek J, Safadi FF, Rafii A: **Comprehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation.** *Stem Cells Int* 2012, **2012**:658356.
42. da Silva Meirelles L, Caplan AL, Nardi NB: **In search of the in vivo identity of mesenchymal stem cells.** *Stem Cells* 2008, **26**:2287–2299.
43. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badyal S, Bhurung HJ, Giacobino JP, Lazzari L, Huard J, Peault B: **A perivascular origin for mesenchymal stem cells in multiple human organs.** *Cell Stem Cell* 2008, **3**:301–313.
44. Boado RJ, Partridge WM: **Differential expression of alpha-actin mRNA and immunoreactive protein in brain microvascular pericytes and smooth muscle cells.** *J Neurosci Res* 1994, **39**:430–435.
45. Armulik A, Abramsson A, Betsholtz C: **Endothelial/pericyte interactions.** *Circ Res* 2005, **97**:512–523.
46. Betsholtz C, Lindblom P, Gerhardt H: **Role of pericytes in vascular morphogenesis.** *EXS* 2005, **94**:115–125.
47. Bianco P, Robey PG, Simmons PJ: **Mesenchymal stem cells: revisiting history, concepts, and assays.** *Cell Stem Cell* 2008, **2**:313–319.
48. Prockop DJ: **Marrow stromal cells as stem cells for nonhematopoietic tissues.** *Science* 1997, **276**:71–74.
49. Caplan AL: **The mesengenic process.** *Clin Plast Surg* 1994, **21**:429–435.
50. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: **Multilineage potential of adult human mesenchymal stem cells.** *Science* 1999, **284**:143–147.
51. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE: **Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms.** *Circ Res* 2004, **94**:678–685.
52. Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P, Prockop DJ: **Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment.** *Biochem Biophys Res Commun* 2007, **354**:700–706.
53. Valle-Prieto A, Conget PA: **Human mesenchymal stem cells efficiently manage oxidative stress.** *Stem Cells Dev* 2010, **19**:1885–1893.
54. Kros J, Austin P, Beslu N, Kroon E, Humphries RK, Sauvageau G: **In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein.** *Nat Med* 2003, **9**:1428–1432.
55. Zhang CC, Kaba M, Ge G, Xie K, Tong W, Hug C, Lodish HF: **Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells.** *Nat Med* 2006, **12**:240–245.
56. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR 3rd, Nusse R: **Wnt proteins are lipid-modified and can act as stem cell growth factors.** *Nature* 2003, **423**:448–452.
57. Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, Kobayashi H, Hooper AT, Seandel M, Shido K, White IA, Kobayashi M, Witte L, May C, Shawber C, Kimura Y, Kitajewski J, Rosenwaks Z, Bernstein ID, Rafii S: **Endothelial cells are essential for the self-renewal and repopulation of notch-dependent hematopoietic stem cells.** *Cell Stem Cell* 2010, **6**:251–264.
58. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T: **Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche.** *Cell* 2004, **118**:149–161.
59. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT: **Osteoblastic cells regulate the haematopoietic stem cell niche.** *Nature* 2003, **425**:841–846.
60. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L: **Identification of the hematopoietic stem cell niche and control of the niche size.** *Nature* 2003, **425**:836–841.
61. Kollet O, Dar A, Shvitiel S, Kalinkovich A, Lapid K, Zsainberg Y, Tesio M, Samstein RM, Goichberg P, Spiegel A, Elson A, Lapidot T: **Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells.** *Nat Med* 2006, **12**:657–664.
62. Raimondi G, Turnquist HR, Thomson AW: **Frontiers of immunological tolerance.** *Methods Mol Biol* 2007, **380**:1–24.
63. Kuo YR, Chen CC, Goto S, Lin PY, Wei FC, Chen CL: **Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation.** *Clin Dev Immunol* 2012, **2012**:854846.

64. Le Blanc K, Ringden O: **Immunomodulation by mesenchymal stem cells and clinical experience.** *J Intern Med* 2007, **262**:509–525.
65. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J: **Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells.** *Stem Cells Dev* 2012, **21**:2724–2752.
66. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M: **Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.** *J Natl Cancer Inst* 2004, **96**:1593–1603.
67. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC: **Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment.** *Cancer Res* 2007, **67**:11687–11695.
68. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA: **Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.** *Nature* 2007, **449**:557–563.
69. Dvorak HF: **Tumors: wounds that do not heal.** *N Engl J Med* 1986, **315**:1650–1659.
70. Balkwill F, Mantovani A: **Inflammation and cancer: back to Virchow?** *Lancet* 2001, **357**:539–545.
71. Vicari AP, Caux C: **Chemokines in cancer.** *Cytokine Growth Factor Rev* 2002, **13**:143–154.
72. Ginestier C, Charafe-Jauffret E, Birnbaum D: **Breast tumor microenvironment: in the eye of the cytokine storm.** *Cell Cycle* 2011, **10**(15):2420–2421.
73. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, Ben-Baruch A: **Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma.** *Cancer Res* 1999, **59**:4681–4687.
74. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM: **CXC chemokines in angiogenesis.** *J Leukoc Biol* 2000, **68**:1–8.
75. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C: **Antitumor effects of the mouse chemokine 6CKine/SLC through angiostatic and immunological mechanisms.** *J Immunol* 2000, **165**:1992–2000.
76. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A: **Involvement of chemokine receptors in breast cancer metastasis.** *Nature* 2001, **410**:50–56.
77. Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, Inoue H, Mori M: **Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma.** *Cancer Res* 2002, **62**:2937–2941.
78. Malek JA, Martinez A, Mery E, Ferron G, Huang R, Raynaud C, Jouve E, Thiery JP, Querleu D, Rafii A: **Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis.** *J Transl Med* 2012, **10**:121.
79. Wels J, Kaplan RN, Rafii S, Lyden D: **Migratory neighbors and distant invaders: tumor-associated niche cells.** *Genes Dev* 2008, **22**:559–574.
80. Abramsson A, Lindblom P, Betsholtz C: **Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors.** *J Clin Invest* 2003, **112**:1142–1151.
81. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR, Buckanovich RJ: **Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production.** *J Clin Invest* 2011, **121**:3206–3219.
82. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB: **Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses.** *Stem Cells* 2008, **26**:99–107.
83. Cai H, Xu Y: **The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells.** *Cell Commun Signal* 2013, **11**:31.
84. Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh D-S, Yoon M-S, Chang CL, Jung JS, Kim JH: **Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells.** *Stem Cells* 2008, **26**:789–797.
85. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, Alison MR, Wright NA: **Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts.** *Cancer Res* 2004, **64**:8492–8495.
86. Cho JA, Park H, Lim EH, Kim KH, Choi JS, Lee JH, Shin JW, Lee KW: **Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts.** *Gynecol Oncol* 2011, **123**:379–386.
87. Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H: **HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.** *J Clin Invest* 2012, **122**:3603–3617.
88. Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, Marini F: **Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.** *Int J Hematol* 2007, **86**:8–16.
89. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC: **TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.** *Cancer Res* 2013, **73**:5016–5028.
90. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselini I, Gordon A, Pustilnik T, Curiel DT, Galanaud P, Capron F, Emilie D, Curiel TJ: **Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.** *Nat Med* 2001, **7**:1339–1346.
91. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR: **Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.** *Cancer Res* 2002, **62**:5930–5938.
92. Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pirani P, Florio T, Schettini G: **Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation.** *Exp Cell Res* 2005, **308**:241–253.
93. Kukreja P, Abdel-Mageed AB, Mondal R, Liu K, Agrawal KC: **Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation.** *Cancer Res* 2005, **65**:9891–9898.
94. Peng SB, Peek V, Zhai Y, Paul DC, Lou Q, Xia X, Eessalu T, Kohn W, Tang S: **Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells.** *Mol Cancer Res* 2005, **3**:227–236.
95. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, Emilie D, Terrasa M, Lackner A, Curiel TJ, Carmeliet P, Zou W: **CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.** *Cancer Res* 2005, **65**:465–472.
96. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: **Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.** *Cell* 2005, **121**:335–348.
97. Dalerba P, Cho RW, Clarke MF: **Cancer stem cells: models and concepts.** *Annu Rev Med* 2007, **58**:267–284.
98. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM: **Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells.** *Cancer Res* 2006, **66**:9339–9344.
99. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP: **Identification and characterization of ovarian cancer-initiating cells from primary human tumors.** *Cancer Res* 2008, **68**:4311–4320.
100. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C: **Cancer stem cell definitions and terminology: the devil is in the details.** *Nat Rev Cancer* 2012, **12**:767–775.
101. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: **Prospective identification of tumorigenic breast cancer cells.** *Proc Natl Acad Sci U S A* 2003, **100**:3983–3988.
102. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS: **Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks.** *Cancer Res* 2011, **71**:614–624.
103. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS: **CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.** *J Clin Invest* 2010, **120**(2):485–497.
104. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, Longaker MT, Weissman IL: **Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.** *Nature* 2010, **466**:133–137.

105. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF: **Phenotypic characterization of human colorectal cancer stem cells.** *Proc Natl Acad Sci U S A* 2007, **104**:10158–10163.
106. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ: **Prospective identification of tumorigenic prostate cancer stem cells.** *Cancer Res* 2005, **65**:10946–10951.
107. Bapat SA, Mali AM, Koppikar CB, Kurrey NK: **Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer.** *Cancer Res* 2005, **65**:3025–3029.
108. Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, Tomao S: **Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach.** *J Exp Clin Cancer Res* 2013, **32**:48.
109. Tomao F, Papa A, Strudel M, Rossi L, Lo Russo G, Benedetti Panici P, Ciabatta FR, Tomao S: **Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.** *J Cancer* 2014, **5**:301–310.
110. Kusumbe AP, Bapat SA: **Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy.** *Cancer Res* 2009, **69**:9245–9253.
111. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ: **Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.** *Cancer Res* 2011, **71**:3991–4001.
112. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W: **Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.** *Int J Cancer* 2012, **130**:29–39.
113. Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, Thompson EW, Findlay JK, Ahmed N: **Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.** *Mol Cancer* 2013, **12**:24.
114. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS: **c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling.** *Oncogene* 2013, **32**:2767–2781.
115. Pasquier J, Rafii A: **Role of the microenvironment in ovarian cancer stem cell maintenance.** *Biomed Res Int* 2013, **2013**:630782.
116. Seo JH, Jeong KJ, Oh WJ, Sul HJ, Sohn JS, Kim YK, Cho do Y, Kang JK, Park CG, Lee HY: **Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin.** *Cancer Lett* 2010, **288**:50–56.
117. Waugh DJ, Wilson C: **The interleukin-8 pathway in cancer.** *Clin Cancer Res* 2008, **14**:6735–6741.
118. Paget S: **The distribution of secondary growths in cancer of the breast.** *Lancet* 1889, **8**(2):98–101.
119. Tarin D, Price JE, Kettlewell MGW, Souter RG, Vass ACR, Crossley B: **Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts.** *Cancer Res* 1984, **44**:3584–3592.
120. Kaplan RN, Rafii S, Lyden D: **Preparing the 'soil': the Premetastatic Niche.** *Cancer Res* 2006, **66**:11089–11093.
121. Psaila B, Lyden D: **The metastatic niche: adapting the foreign soil.** *Nat Rev Cancer* 2009, **9**:285–293.
122. Erler JT, Banneth KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia AJ: **Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.** *Cancer Cell* 2009, **15**:35–44.
123. Kenny HA, Kaur S, Coussens LM, Lengyel E: **The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.** *J Clin Invest* 2008, **118**:1367–1379.
124. Zhang XH, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, Smid M, Foekens JA, Massague J: **Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma.** *Cell* 2013, **154**:1060–1073.
125. Cheng B, Lu W, Xiaoyun W, YaXia C, Xie X: **Extra-abdominal metastases from epithelial ovarian carcinoma: an analysis of 20 cases.** *Int J Gynecol Cancer* 2009, **19**:611–614.
126. Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, Selvaggi L: **Distant metastases in ovarian carcinoma.** *Int J Gynecol Cancer* 2003, **13**:125–129.
127. Hudson LG, Zeineldin R, Stack MS: **Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression.** *Clin Exp Metastasis* 2008, **25**:643–655.
128. Veatch AL, Carson LF, Ramakrishnan S: **Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells.** *Int J Cancer* 1994, **58**:393–399.
129. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P: **PGE (2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.** *Cancer Res* 2011, **71**:7463–7470.
130. Zhu GG, Risteli J, Puistola U, Kauppila A, Risteli L: **Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity.** *Cancer Res* 1993, **53**:5028–5032.
131. Mustea A, Pirvulescu C, Kongsen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J: **Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.** *Cytokine* 2008, **42**:77–84.
132. Lafky JM, Wilken JA, Baron AT, Maihle NJ: **Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.** *Biochim Biophys Acta* 2008, **1785**:232–265.
133. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC: **Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies.** *J Natl Cancer Inst* 1996, **88**:1810–1820.
134. Chene G, Penault-Llorca F, Le Bouedec G, Mishellany F, Dauplat MM, Jaffeux P, Aublet-Cuvelier B, Pouly JL, Dechelotte P, Dauplat J: **Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk.** *Int J Gynecol Cancer* 2009, **19**:65–72.
135. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih IM: **Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.** *Cancer Biol Ther* 2006, **5**:779–785.
136. Freedman RS, Deavers M, Liu J, Wang E: **Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC).** *J Transl Med* 2004, **2**:23.
137. Rafii A, Mirshahi P, Poupot M, Fausat A-M, Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J, Bergalet J, Querleu D, Dagonnet F, Fourni J-J, Marie J-P, Pujade-Lauraine E, Favre G, Soria J, Mirshahi M: **Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours.** *PLoS One* 2008, **3**:e3894.
138. Castells M, Thibault B, Mery E, Golzio M, Pasquet M, Hennebelle I, Bourin P, Mirshahi M, Delord JP, Querleu D, Couderc B: **Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages.** *Cancer Lett* 2012, **326**:59–68.
139. Castells M, Milhas D, Thibault B, Rafii A, Delord JP, Couderc B: **Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation.** *Cell Death Dis* 2013, **4**:e887.
140. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: **Cancer statistics, 2008.** *CA Cancer J Clin* 2008, **58**:71–96.
141. Shostak A, Chakrabarti E, Hirszel P, Maher JF: **Effects of histamine and its receptor antagonists on peritoneal permeability.** *Kidney Int* 1988, **34**:786–790.
142. Muijsken MA, Heezius HJ, Verhoef J, Verbrugh HA: **Role of mesothelial cells in peritoneal antibacterial defence.** *J Clin Pathol* 1991, **44**:600–604.
143. Kenny HA, Krausz T, Yamada SD, Lengyel E: **Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum.** *Int J Cancer* 2007, **121**:1463–1472.
144. Jones LM, Gardner MJ, Catterall JB, Turner GA: **Hyaluronic acid secreted by mesothelial cells: a natural barrier to ovarian cancer cell adhesion.** *Clin Exp Metastasis* 1995, **13**:373–380.
145. Kenny H, Nieman K, Mitra A, Lengyel E: **The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer.** *Cancer Disc* 2011, **1**:100–102.
146. Zhang XY, Pettengell R, Nasiri N, Kalia V, Dalgleish AG, Barton DP: **Characteristics and growth patterns of human peritoneal mesothelial cells: comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources.** *J Soc Gynecol Investig* 1999, **6**:333–340.
147. Wang E, Ngalmé Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM: **Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer.** *Clin Cancer Res* 2005, **11**:113–122.
148. Sako A, Kitayama J, Yamaguchi H, Kaisaki S, Suzuki H, Fukatsu K, Fujii S, Nagawa H: **Vascular endothelial growth factor synthesis by human**

- omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. *J Surg Res* 2003, **115**:113–120.
149. Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR Jr, Ruff LE, Skubitz AP: **Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids.** *Am J Pathol* 2001, **159**:2071–2080.
 150. Gardner MJ, Jones LM, Catterall JB, Turner GA: **Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis.** *Cancer Lett* 1995, **91**:229–234.
 151. Iwanicki M, Davidowitz R, Ng M, Besser A, Muranem T, Merritt M, Danuser G, Ince T, Brugge J: **Ovarian cancer spheroids use myosin-generated force to clear the mesothelium.** *Cancer Disc* 2011, **1**:144–147.
 152. Klopp AH, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M, Debeb B, Woodward W, Schmandt R, Broaddus R, Lu K, Kolonin MG: **Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors.** *Clin Cancer Res* 2012, **18**:771–782.
 153. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: **Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.** *J Clin Oncol* 2002, **20**:1248–1259.
 154. Pignata S, Cannella L, Leopardi D, Pisano C, Bruni GS, Facchini G: **Chemotherapy in epithelial ovarian cancer.** *Cancer Lett* 2011, **303**:73–83.
 155. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A: **Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.** *Lancet* 2010, **376**(9737):245–251.
 156. Pfisterer J, Ledermann JA: **Management of Platinum-Sensitive Recurrent Ovarian Cancer.** *Semin Oncol* 2006, **33**:12–16.
 157. Meads MB, Gatenby RA, Dalton WS: **Environment-mediated drug resistance: a major contributor to minimal residual disease.** *Nat Rev Cancer* 2009, **9**:665–674.
 158. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, Frei E 3rd: **Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.** *Science* 1990, **247**:1457–1461.
 159. Pasquier J, Galas L, Boulange-Lecomte C, Rioult D, Bultelle F, Magal P, Webb G, Le Foll F: **Different modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 breast cancer cells.** *J Biol Chem* 2012, **287**:7374–7387.
 160. Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, Polycarpe D, Sadelain M, Larson SM: **Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells.** *Proc Natl Acad Sci U S A* 2005, **102**:1933–1938.
 161. Chua T, Robertson G, Liauw W, Farrell R, Yan T, Morris D: **Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.** *J Cancer Res Clin Oncol* 2009, **135**:1637–1645.
 162. Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, Classe JM, Bereder JM, Quenet F, Meeus P, Marchal F, Morice P, Elias D: **Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study.** *Eur J Surg Oncol* 2010, **36**:589–593.

doi:10.1186/s12967-014-0271-5

Cite this article as: Touboul et al.: Role of mesenchymal cells in the natural history of ovarian cancer: a review. *Journal of Translational Medicine* 2014 **12**:271.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

